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Abstract.  This paper describes studies on the migra- 
tory behavior of epidermal growth factor (EGF) recep- 
tor kinase using antibodies that are specific for either 
the kinase domain or the extracellular domain of the 
receptor.  Antiserum was raised to a 42,000-D  subfrag- 
ment of EGF receptor, which was shown earlier to 
carry the kinase catalytic site but not the EGF-binding 
site.  Another antiserum was raised to the pure intact 
170,000-D  EGF receptor.  The specificities of these an- 
tibodies were established by immunoprecipitation and 
immunoblotting experiments. The domain specificity 
was examined by indirect immunofluorescent staining 
of fixed cells. The anti-42-kD peptide antibody could 
bind specifically to EGF receptors of both human and 
murine origin and was found to be directed to the 
cytoplasmic part of the molecule. It did not bind to 
EGF receptor-negative cells, which contained other 
types of tyrosine kinases.  The antibodies raised against 
the intact receptor recognized only EGF receptor- 
specific epitopes and were directed to the extracellular 
part of the molecule. 
The anti-receptor antibodies described above were 
used to visualize the cyclic locomotory behavior of 
EGF receptor kinase under various conditions of EGF 
stimulation and withdrawal. The receptor was exam- 
ined in fixed and permeabilized cells by indirect im- 
munofluorescent staining. The results demonstrate the 
following: (a) the receptor kinase domain migrates to 
the perinuclear region upon challenge with EGF; (b) 
both extracellular and cytoplasmic domains of the 
receptor are involved in migration as a unit; (c) with- 
drawal of EGF results in rapid recycling of the 
perinuclear receptors to the plasma membrane;  (d) 
this return to the cell surface is inhibited by methyl- 
amine, chloroquine, and monensin; and (e) neither the 
internal migration nor the recycling process is blocked 
by inhibitors of protein biosynthesis. 
T 
HE epidermal growth factor (EGF) 1 receptor is a plas- 
ma membrane protein that has been implicated in the 
regulation of cell proliferation and cancer causation 
(17). It is a single chain polypeptide of 170,000--180,000 D that 
has an externally facing EGF-binding domain and a cytoplas- 
mically facing tyrosine-specific protein kinase site (10, 13, 
41). Although no significant biological function has yet been 
assigned to the tyrosine kinase site, the importance of tyro- 
sine kinases in biology is apparent in the stringent conserva- 
tion  of these  molecules  through  prolonged  evolutionary 
times,  and  in  the  remarkable  homologies  seen  between 
different tyrosine kinases in their catalytic domains (25). 
Some of the questions that can be asked regarding receptor 
tyrosine kinases are as follows: (a) What is the molecular ba- 
sis for growth factor-induced activation of the receptor ki- 
nase site?  (b)  What is the subcellular site of action of the 
receptor kinase? Is it at the plasma membrane or elsewhere? 
If the site of action is other than plasma membrane, what 
1.  Abbreviations  used  in  this paper:  DME,  Dulbecco's modified Eagle's 
medium; EGF, epidermal growth factor; EBSS, Earle's balanced salt so- 
lution. 
structural features control the migration to the inside of the 
cell? 
We have answered the first question to some extent. Our 
in vitro studies provide experimental evidence for the suppo- 
sition that the EGF receptor is an allosteric enzyme that can 
interconvert between active (monomeric) and inactive (di- 
meric) forms, and that EGF, the ligand, activates the kinase 
by shifting the equilibrium towards the catalytically active 
monomeric  form  (6).  These  observations  on  the  activa- 
tion/inactivation cycle of the kinase site led us to the studies 
described here. 
Receptors for many ligands, such as asialoglycoproteins, 
transferrin, and low density lipoprotein, are known to display 
a characteristic migratory behavior (3, 9, 22). After binding 
to their ligands, these receptors cluster or segregate in coated 
pits and then internalize. Within internal organelles (endo- 
somes), the receptor dissociates from its ligand, and the free 
receptor recycles back to the cell surface. This round-trip 
itinerary serves to accumulate the ligand (often a nutrient) 
inside the cell. 
EGF bound to cell-surface receptor is also known to un- 
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is co-internalized and is subjected to slow proteolysis (t,~ > 
1 h) (4,  14, 16, 19, 38).  Since EGF is not a simple nutrient, 
what could be  the biological significance of this internal 
migration of the receptor? It is thought that this process 
serves a regulatory function by mediating rapid lysosomal 
destruction of excess EGF and receptor. However it is likely 
that this migratory process may have yet another biological 
role that is more closely related to the mitogenic function of 
EGF receptor.  This is suggested by the fact that the EGF 
receptor is an enzyme. If the target substrate for the receptor 
kinase is located within the interior of the cell, it will be 
necessary for the receptor and its substrate to come into close 
contact; one way to achieve this contact would be through 
receptor internalization. 
To visualize the movement of receptor kinase domain dur- 
ing EGF stimulation and withdrawal, we needed to develop 
an antibody directed to that domain. Recently we isolated, 
by proteolysis, a 42,000-D receptor domain that retains the 
kinase catalytic activity of the intact 170-kD EGF receptor 
but loses EGF-binding and kinase-regulatory functions (2). 
Here  we  describe  the  development of an  immunological 
probe for this human EGF receptor-derived 42-kD tyrosine 
kinase. The antibody was found to recognize only the cyto- 
plasmic part of EGF receptor and showed no reaction with 
other receptor kinases. The specificity of this antibody and 
other  anti-EGF-receptor  antibodies  used  here  was  estab- 
lished by immunoprecipitation and immunoblot analyses. 
We used these specific antibodies in indirect immunofluores- 
cent staining studies to visualize the subcellular location of 
EGF receptor kinase under various conditions of stimulation 
and withdrawal. The results demonstrate that the EGF recep- 
tor kinase displays a cyclic locomotion that is controlled by 
its state of activation. The cycle of locomotion can be dis- 
turbed by certain drugs that inhibit receptor mitogenicity but 
not by inhibitors of protein biosynthesis. Some implications 
of these findings are discussed. 
Materials and Methods 
Materials 
EGF was purified from mouse submaxillary glands (34)  and radiolabeled 
by the chloramine-T procedure (13).)'-32p-ATP  was prepared with inor- 
ganic 32p (ICN K  &  K  Laboratories Inc., Plainview, NY)  and Gamma- 
Prep A kit (Promega Biotech, Madison, WI) following the manufacturer's 
instruction. The following reagents were from Sigma Chemical Co.  (St. 
Louis,  MO):  rhodamine- and  fluorescein-conjugated second antibodies, 
methylamine, monensin, and chloroquine. 
Cell Culture 
Human epidermoid A431 carcinoma cells, human fetal lung WI-38 fibro- 
blasts (nonsenescent, a kind gift from Dr. Paul Philips of Wistar Institute), 
murine Swiss 3T3 fibroblasts, and NR-6 fibroblasts (EGF receptorless vari- 
ants of 3T3)  were grown in Dulbecco's modified Eagle's medium (DME) 
supplemented with 10%  fetal bovine serum and  10 ~tg/ml gentamycin. 
Immunological Tools 
Anti-42-kD  Peptide Antibody.  A  rabbit antiserum was generated to the 
pure 42-kD kinase as follows. EGF receptor was solubilized from human 
A431 plasma membranes and then purified by EGF affinity chromatography 
as described (2, 6,  15). The pure EGF receptor (50 lag) was incubated at 
20°C for 30 min with 2 lag/ml trypsin (pure, crystalline) in 0.2 ml of 20 mM 
Hepes, pH 7.4,  5% glycerol, 0.2% Triton X-100 (2).  This resulted in the 
generation of  the 42-kD kinase. After stopping trypsin action with 0.2 gmol 
of  N-p-tosyl-L-lysinechloromethylketone,  the mixture was subjected to non- 
denaturing electrophoresis on 5-20% gradient polyacrylamide gels at pH 
8.8 as described earlier (2, 35). After the run, the gel (ll-cm long) was cut 
into  11  slices. The undegraded  170-kD receptor and other EGF-binding 
forms were recovered in gel slices 1 and 2 (trypsin was also recovered near 
the top of the gel). The 42-kD peptide was recovered in gel slices 5 and 6 
(2). These slices (5 and 6) were homogenized with phosphate-buffered sa- 
line (PBS), emulsified with an equal volume of Freund's complete adjuvant, 
and then injected intradermally at multiple sites into dorsal surfaces of rab- 
bits (New Zealand, Albino, 3-4-mo-old females). The rabbits were rein- 
jected twice at 3-wk intervals with the antigen emulsified in Freund's incom- 
plete adjuvant. 8 d after the last injection, the rabbits were bled. The IgG 
fraction of the antiserum was purified by protein A-Sepharose column chro- 
matography using 0.1 M glycine-HCl, pH 3.0 as the eluting buffer.  All the 
antibody activity was bound to the column, and >90%  was eluted.  The 
eluted IgG  was  neutralized immediately with Tris,  dialyzed extensively 
against PBS, and stored at -70°C. This antibody binds specifically to EGF 
receptors of both human and murine origin, and binds only to receptor 
cytoplasmic domain (see Results). 
Anti-170-kD Receptor Antibody.  A rabbit antiserum was generated to 
the intact and pure 170-kD human EGF receptor as described (37). The solu- 
bilized and EGF affinity-purified human EGF receptor (2, 6,  15) was sub- 
jected to SDS PAGE. The stained gel band containing the 170-kD receptor 
(•40  gg protein) was used to immunize rabbits as described in the previ- 
ous  section.  The IgG fraction of the antiserum was purified on protein 
A-Sepharose columns as described above. The anti-170-kD  receptor lgG 
binds specifically to EGF receptors of both human and murine origin (see 
Results). 
Murine Antibody Specific for the Human Receptor. A murine antise- 
rum was obtained after immunization of C57BL/6 mice with a mouse-hu- 
man somatic hybrid cell line cl 21, which contains human chromosome 7 
as the only human chromosome (7, 15). This antiserum has been extensively 
characterized to react exclusively with the EGF receptor on the cell surface 
(7,  15). The IgG fraction of this antiserum specifically immunoprecipitates 
the human EGF receptor, and it inhibits the binding of EGF to the human 
receptor (15). 
Western Blotting Method 
This was done as described (36).  Plasma membrane fractions of human 
A431 cells and mouse 3T3 cells were isolated (6, 39) and subjected to SDS 
PAGE under reducing conditions. The electrophoretically separated pro- 
teins were electrophoretically transferred to  nitrocellulose sheets as de- 
scribed by Towbin et al. (40) using a Bio-Rad apparatus (Bio-Rad Laborato- 
ries, Richmond, CA). The electrode buffer contained 25 mM Tris/192 mM 
glycine/20% methanol (vol/vol) at pH 8.3. The run time was 'M0 h (at 250 
mA, 20 V). This ensured efficient transfer of the 170-kD EGF receptor and 
other high molecular weight proteins. After transfer, the nitrocellulose blots 
were soaked in 3% bovine serum albumin (BSA), 0.15 M NaCI, 10 mM Tris- 
HCI, pH 7.4 for 5 h at 20°C to saturate additional protein binding sites. They 
were then rinsed in saline and incubated at 20°C for 2 h with anti-EGF- 
receptor rabbit IgG or nonimmune rabbit lgG (0.1-1 mg IgG/ml) in 3 % 
BSA/0.15 M  NaCI/10  mM Tris-HCl, pH 7.4.  The antibody-treated sheets 
were washed extensively in saline, then incubated with goat anti-rabbit IgG 
antibody (100 lag/ml)  in saline-BSA at 20°C for 2  h,  again washed and 
finally incubated at 20°C for 6 h with 1251-labeled protein A (10  s cpm, 500 
ng) in saline-BSA. The papers were then washed extensively in saline, dried 
with a hair dryer, and then subjected to autoradiography. 
Immunoprecipitation of uSI-EGF-Receptor Covalent 
Complex  from Murine Fibroblasts 
3T3  or NR-6 cell monolayers in  10-cm dishes were washed with Earle's 
balanced  salt  solution  (EBSS)  containing  20  mM  Hepes,  pH  7.4  and 
1 mg/ml BSA (EBSS-Hepes-BSA), and then incubated at 20°C for 30 min 
with 30 nM 1251-EGF (150,000 cpm/ng). Under these conditions the recep- 
tor becomes covalently linked to t251-EGF (11). The cells containing radio- 
labeled receptor were washed with EBSS-Hepes and lysed in 200 lal of a 
buffer consisting of 10 mM sodium phosphate, pH 7.4, 0.15 M NaC1, 6 mM 
phenylmethylsulfonyl fluoride, 3%  Triton X-100, 5 mM EDTA,  150 mM 
benzamidine, and  1 U/ml aprotinin.  The lysate was frozen-thawed three 
times, clarified by centrifugation, and then subjected to immunoprecipita- 
tion as follows. The lysate was incubated at 4°C for 1 h with rabbit immune 
IgG or nonimmune IgG (30 lag). The immune complexes were isolated by 
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lococcus  aureus  (10  mg),  and  then washing  the bacteria  with  20  mM 
Hepes/0.15  M  NaCI containing 1 mg/ml BSA and 0.1% Triton X-100. The 
bound radioactivity was eluted by boiling for 2 min in 1% SDS containing 
0.1 M I~-mercaptoethanol  in 0.15 M Tris-HCl, pH 6.8, and subjected to SDS 
PAGE and autoradiography using Kodak X-Omat films and DuPont Cronex 
Lightning Plus  intensifying screens (DuPont  Co.,  Diagnostic  and  Bio- 
Research Systems, Wilmington, DE) (2, 6,  15). 
Immunoprecipitation Experiments with Crude 
Extracts ofA431 Cells and Mouse Liver Membranes 
Plasma membranes (1 rag) from human A431 cells (6, 39) and mouse liver 
(5) were extracted at 20°C for 30 rain with 1% Triton X-100 in 300 ~tl of 
20  mM  Hepes,  pH 7.4,  10%  glycerol, 20  txg/ml  leupeptin.  An aliquot 
of the clarified extract (200  p.l) was incubated at 4°C for 1 h with 16 mg 
of  S. aureus containing bound 60 ~tg of  rabbit immune IgG (anti-42-kD pep- 
tide antibody or anti-170-kD  receptor antibody) or nonimmune IgG, in 60 
Ixl of 20 mM Hepes, pH 7.4/10%  glycerol. The bacteria were then washed 
three times with 20 mM Hepes/0.15  M NaC! containing 1 mg/ml BSA and 
0.1%  Triton X-100 (Hepes/NaC1/BSA/Triton). The washed bacteria were 
suspended in 40 ~tl of Hepes/NaCl/BSA/Triton containing 1.2 mM MnCI2 
and either no EGF or 1 IxM EGE After 10 rain at 4°C, phosphorylation was 
initiated by the addition of 10 ~tl of 25 lxM )'-32p-ATP (100 cpm/fmol). Af- 
ter incubation at 4°C for 30 min, the bacteria were washed, and the bound 
radioactivity was analyzed by SDS PAGE and autoradiography (2, 6,  15). 
Indirect Immunofluorescent Staining 
For these experiments, cells were grown on glass coverslips (1-cm diam) in 
24-well multiwells. These were treated with EGF and/or other reagents (see 
figure legends), and then subjected to either of the three following methods 
of fixation: (a) Fixation without permeabilization. Cell monolayers on glass 
coverslips were fixed with 3% paraformaldehyde-PBS for 10 min at 4°C, 
washed with PBS, and then rid of excess paraformaldehyde by treatment 
with 50 mM NI-hCI-PBS at 4°C for 40 rain (20). (b) Fixation followed by 
Triton X-100 permeabilization. Cell monolayers fixed with paraformalde- 
hyde as in a  were incubated at 20°C for 5 min with 0.5% Triton X-100 in 
10 mM Hepes, 0.3 M  sucrose, 3 mM MgCI2,  50 mM NaCI, pH 7.4,  and 
then washed three times with ice-cold PBS (31). (c) Methanol permeabiliza- 
tion.  The cell monolayers on glass slides were incubated with absolute 
methanol at 20°C for 10 min, then washed three times with ice-cold PBS 
(21). 
Coverstips treated as above were rinsed three times with ice-cold DME 
and incubated at 4°C for 1 h with 100 ~1 of DME containing 40-200  ~tg 
of  rabbit (or mouse) immune IgG or nonimmune IgG. The treated coverslips 
were washed with DME and then incubated at 4°C for 1 h with 100 ~tl of 
DME containing rhodamine-conjugated goat anti-rabbit IgG antibody or 
anti-mouse IgG antibody (Sigma Chemical Co.; dilution 1:200 to 1:50). Fi- 
nally, the coverslips were extensively washed with DME, mounted on glass 
slides,  and  photographed using  10-20-s  exposures  for  A431 cells  and 
60-120-s exposures for fibroblasts. 
12JI-EGF Binding Assay 
Cell monolayers, treated as described in Fig. 10 legend, were washed, then 
incubated at 4°C for 2 h with 20 nM ~25I-EGF (150,000 cpm/ng) in 1 mi of 
EBSS containing 20 mM Hepes, pH 7.4,  and 1 mg/ml BSA (13, 14). After 
incubation the monolayers were washed free of unbound radioactivity, solu- 
bilized  with  1  ml  of  1  M  NaOH,  and  counted  in  a  gamma  counter. 
Nonspecific binding was determined in the presence of 5  p.M unlabeled 
EGE 
Results 
Antibody Specificity 
Western blot analyses of crude membranes from A431  and 
3T3 cells show that the rabbit anti-170-kD  antibody binds 
specifically only to a  170-kD polypeptide (Fig.  1). The non- 
170-kD bands seen also bind to nonimmune IgG (Fig. 1). The 
170-kD band co-migrates with the polypeptide that becomes 
covalently labeled with ~25I-EGF (Fig.  1). Similar immuno- 
Figure 1. Antibody specificity depicted by Western blotting and im- 
munoprecipitation analyses. A431 membranes (1 lag protein) and 
31"3 membranes (50 ~tg protein) were subjected to SDS gel elec- 
trophoresis and Western blotting with anti-170-kD receptor rabbit 
antibody  (A)  or  nonimmune  rabbit  IgG  (N)  as  described  in 
Materials and Methods. The autoradiographic exposure times for 
the  Western blots  with  A431  and  3T3  cells were  15  h  and  7  d, 
respectively.  The  immunoprecipitation  experiments  were  con- 
ducl~l with 3T3 cell receptors covalently linked to mI-EGF using 
anti-170-kD receptor rabbit antibody as described in Materials and 
Methods. Identical experiments with 3T3  cells using nonimmune 
IgG or with NR-6 cells using antibody produced no immunopre- 
cipitated protein at  170 kD or elsewhere. 
blotting experiments with the anti-42-kD peptide antibody 
also revealed a high degree of specificity for the EGF recep- 
tor (not shown)  and  for the EGF receptor-derived 42-kD 
peptide (not shown) which was shown earlier to represent the 
tyrosine kinase domain of the receptor (2). 
The specificity of the anti-42-kD peptide antiserum and 
the  anti-170-kD  receptor antiserum  was  further examined 
using Triton X-100 solubilized extracts of human A431  cell 
membranes  and  mouse hepatic  membranes.  As  shown  in 
Fig.  2  the  anti-42-kD  immune IgG  immunoprecipitates a 
170-kD  protein  (from both  human  and  murine  sources), 
which retains the capacity for EGF-stimulatable autophos- 
phorylation in  the isolated antibody-bound state.  In A431 
cells  it  also  immunoprecipitates  a  150-kD  EGF  receptor 
(Fig. 2), which is a proteolytic degradation product of the 
170-kD receptor (2). A similar result was also obtained with 
the anti-170-kD  receptor antibody (not shown). 
Domain Specificity of the Antibody Revealed 
by Indirect Immunofluorescent Staining of  Cells 
The anti-170-kD  receptor antibody reacted well (at the plas- 
ma membrane) with permeabilized or nonpermeabilized hu- 
man A431 cells (Fig. 3) and murine 3T3 cells (Fig. 4 B). No 
binding  was  seen with murine NR-6  cells (Fig.  4  C),  an 
EGF-binding negative variant of 3T3 (13, 22). Thus the epi- 
topes recognized by this antibody are EGF receptor-specific, 
and are present on the extracellular part of the receptor. 
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tion of  active EGF receptor ki- 
nase from detergent extracts of 
human A431 ceils and mouse 
hepatic  membranes  by  anti- 
42-kD  peptide  antibody  and 
nonimmune (NI) rabbit IgG. 
Experimental procedures are 
described  in  Materials  and 
Methods. 
The anti-42-kD peptide antibody showed no reaction with 
nonpermeabilized human A431 ceils (Fig. 3) or murine 3T3 
cells  (not  shown).  However permeabilization of the  cells 
with methanol or with Triton X-100 revealed plasma mem- 
brane-localized reactions with the antibody in both A431 
cells (Fig.  3) and 3T3 cells (Fig. 4 A). This indicates that 
the anti-42-kD peptide antibody is directed to receptor epi- 
topes that are present exclusively in the cytoplasmic domain 
of the molecule. 
The EGF receptor-negative mouse NR-6 cell line (13, 32) 
showed no reaction with the anti-42-kD antibody even in the 
permeabilized state (Fig. 4  C). 
Visualization  of the Migratory Behavior of 
Receptor Kinase after EGF Treatment of  Cells 
Migratory behavior of the receptor in murine 3T3 cells and 
human WI-38 cells was visualized by indirect immunofluo- 
rescent staining of permeabilized cells using the anti-42-kD 
peptide  antibody  and  the  anti-170-kD  receptor  antibody 
(Figs. 4 and 5). In experiments with the human WI-38 cell 
line, a murine antibody (15) directed to receptor extracellular 
domain was also used.  In cells that were not treated with 
EGF, the receptor localized in the plasma membrane (Figs. 
3-5). In cells that were treated with EGF at 37°C a perinu- 
clear localization was seen, irrespective of the type of anti- 
body used for staining (Figs. 4 and 5). The receptors in hu- 
man A431 cells also showed a similar change in localization 
upon challenge with 40 nM  EGF (not shown).  The EGF- 
dependent change in receptor localization was  not seen in 
cells that were treated with EGF at 4°C  (not shown).  The 
migratory process was unaffected in the presence of cyclo- 
heximide (not shown). 
The presence of 10 mM methylamine enhanced the EGF- 
dependent perinuclear accumulation of receptors (Fig. 4 A). 
Chloroquine (100 I.tM) also had a similar effect (not shown). 
However, these reagents alone, in the absence of EGF, did 
not affect receptor translocation to any significant extent. 
Effect of  EGF Withdrawal on Receptor Location 
Cells treated with EGF at 37°C for 30 min showed no detect- 
able EGF receptor-specific surface fluorescence in the non- 
permeabilized state  (Fig.  6  A).  Permeabilization of these 
cells showed the presence of EGF receptors in the perinu- 
clear region (Figs. 4-6). However, withdrawal of EGF from 
the medium and subsequent incubation at 37°C  resulted in 
a rapid disappearance of these perinuclear receptors, accom- 
panied by their appearance in the plasma membrane (Fig. 6). 
The process was  seen irrespective of the type of antibody 
used for staining (Fig. 6, A and B), and was observed in both 
murine 3T3 cells (Fig.  6) and  in human WI-38 cells (not 
shown).  In  double  immunofluorescence experiments with 
WI-38  cells using  rabbit  anti-42-kD  antibody and  mouse 
anti-human  receptor antibody, we found colocalization of 
fluorescein (anti-mouse) and  rhodamine (anti-rabbit)  fluo- 
rescence during EGF treatment and EGF withdrawal  (not 
shown), suggesting that both domains of the receptor inter- 
nalize and recycle in unison. 
Translocation of receptors from the perinuclear region to 
the cell surface did not occur at 4°C (not shown). The pres- 
ence of cycloheximide had no effect on this rapid phenome- 
non (Fig. 6 B), suggesting that the process involves recycling 
of  receptors,  rather  than  insertion  of  newly  synthesized 
receptors into  the  plasma  membrane.  The  migration  was 
blocked in the presence of 10 mM methylamine (Fig. 6 B), 
10 ~M monensin, and  100 p.M chloroquine (not shown). 
The phenomenon was  reexamined by  ~25I-EGF binding. 
Cells treated with unlabeled EGF (40 nM) at 37°C for 20 rain 
showed no detectable ~25I-EGF  binding activity (Fig. 7). We 
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ing of permeabilized and nonpermeabilized 
human A431 cells. (A, C, and E) Paraform- 
aldehyde-fixed  (nonpermeable) cells treated 
with anti-42-kD immune IgG (A), nonim- 
mune  IgG  (C),  anti-170-kD receptor  im- 
mune IgG (E), and then stained with rhoda- 
mine-conjugated goat anti-rabbit  antibody. 
(B, D, and F) Methanol-permeabilized cells 
treated with anti-42 kD immune IgG (B), 
nonimmune  IgG  (D),  anti-170-kD recep- 
tor  immune  IgG  (F),  and  then  stained 
with rhodamine-conjugated goat anti-rab- 
bit antibody. 
tested whether incubation of these cells in EGF-free medium 
at 37°C would result in a return of the receptors to the sur- 
face. This was done by incubating the cells at 4°C for 2 h 
with a  saturating concentration of t25I-EGE In preliminary 
studies we found that cells treated at 4°C for 20 min with or 
without 40 nM EGF, then washed and incubated with 20 nM 
~25I-EGF at 4°C for 2 h, showed the same amount of radio- 
activity bound, irrespective of pretreatment or no treatment 
at 4°C with unlabeled EGE Thus these binding conditions 
allow sufficient equilibration to occur (due to dissociation 
and  reassociation)  between  cell-surface  bound  unlabeled 
EGF (<0.1 pmol) and the added excess (20 pmol) radiola- 
beled EGF, such that cell-bound radioactivity can be used for 
quantitation of surface receptor activity. Fig.  7  shows that 
when EGF-pretreated cells are incubated at 37°C in EGF- 
free medium, there is a progressive gain in  ~2~I-EGF bind- 
ing activity. This gain was blocked by methylamine (Fig. 7). 
In experiments where cells were incubated at 4°C after ex- 
posure to unlabeled EGF, there was no return of receptors 
to the cell surface (Fig.  7). 
The results depicted in Figs. 6 and 7 indicate that internal- 
ized EGF receptors can rapidly recycle to the cell surface in 
a  temperature-sensitive manner. 
The extent of receptor recovery at the surface was drasti- 
cally reduced when the period of  pretreatment with EGF was 
4 h instead of 30 min (not shown). Under such conditions, 
extensive receptor degradation (t,~ i> 1 h) brings about a net 
decrease (i.e., down-regulation [1, 8]) in cellular EGF recep- 
tors (14, 16, 38), thus reducing the number of molecules that 
can recycle. 
Discussion 
EGF  receptor was  the  first  growth  factor receptor to  be 
biochemically characterized.  Subsequent  studies  on other 
growth factor receptors (platelet-derived growth factor recep- 
tor, insulin receptor, and insulin-like growth factor recep- 
tor) have revealed some unusual  characteristics that mark 
them as belonging to a  class quite different from those of 
other types of receptors. (a) Unlike the acetylcholine recep- 
tor and other ion-channel receptor polypeptides which span 
the plasma membrane more than once (12), the EGF and in- 
sulin receptor polypeptides appear to have only single trans- 
membrane  spanning  segments  (41, 42).  (b)  Unlike  the 
ligand-accumulatory receptors (for low density lipoprotein, 
transferrin, asialoglycoproteins, etc.) which have very short 
cytoplasmically facing regions (50-70 residues long) (18, 28, 
43), the growth factor receptors have large cytoplasmic do- 
Murthy et al. Recycling of EGF Receptor Kinase  337 Figure 4. EGF-induced  accumulation  of EGF receptor in the perinuclear region of murine 3T3 cells. (A) Indirect immunofluorescent  stain- 
ing of 3T3 cells with anti-42-kD peptide antibody. (B) Staining of 3T3 cells with anti-170-kD receptor  antibody. (C) Lack of staining of 
permeabilized mouse NR-6 cells with anti-170-kD antibody and anti-42-kD antibody. The 3T3 cells were incubated at 37°C for 30 min 
in DME-0.1% BSA containing 20 nM EGF (or no EGF) and 10 mM methylamine (or no methylamine). (The NR-6 cells were not treated 
with either EGF or methylamine.) Then the monolayers were washed,  fixed, permeabilized with Triton X-100, and subjected to indirect 
immunofluorescent  staining as described in Materials and Methods. The results of fluorescence and phase microscopy are shown in upper 
and lower panels, respectively. 
The Journal of Cell Biology, Volume 103, 1986  338 mains (500-700  residues long) (41, 42).  (c)  Unlike the 13- 
adrenergic receptor, glucagon receptor, and other receptors 
which transmit signals through activation of a separable pro- 
tein kinase,  the growth  factor receptors  have an intrinsic 
ligand-activated kinase catalytic site built into the molecule 
(24,  26, 41, 42). 
Thus growth factor receptors belong to a unique class of 
bipolar  multi-sited  proteins.  The  molecular  and  cellular 
aspects of  how these membrane proteins induce growth stim- 
ulation remain as yet unknown. 
As  with  many  other  ligand-receptor  systems,  EGF  is 
known to be internalized after binding to its receptor. The 
degradative fate of the internalized receptor has been studied 
by covalent affinity labeling (14), and more recently by meta- 
bolic labeling using anti-receptor antibodies (4, 16, 38). Al- 
though the phenomenon has  been  known for quite  some 
time, the precise location of the internalized receptor and the 
possibility of its recycling have been subjects of debate. In 
the present study we have examined location and migration 
of both occupied and unoccupied receptors by using anti- 
receptor antibodies whose specificity for the EGF receptor 
was established by various methods. The antibodies meet the 
following criteria: (a) they can specifically immunoprecipi- 
tate EGF receptors of both human and murine origin (Fig. 
2); (b) the antibodies selectively bind to the EGF receptor 
in immunoblot experiments with A431 and 3T3 membranes 
(Fig.  1); (c) the antibodies do not bind to the NR-6 cell line 
which lacks  EGF-receptors but which does contain other 
related growth factor receptors (Fig. 4  C). 
One of the antibodies we have raised is directed to the ki- 
nase domain of the receptor. By using this antibody we have 
shown  that  the  receptor  kinase  domain  migrates  to  the 
perinuclear/nuclear envelope region in an EGF-dependent 
fashion. Studies with other anti-receptor antibodies indicate 
that both domains of the receptor are involved in migration. 
Inhibitors of protein biosynthesis have no effect on this pro- 
cess, suggesting that the appearance of immunoreactivity in 
the perinuclear region is not due to synthesis of new recep- 
tors in response to EGF, but rather is due to migration of 
pre-existing  receptors  from the plasma  membrane  to  the 
perinuclear region. 
Figure  5.  EGF-induced migration of the  EGF  receptor to  the 
perinuclear region of human WI-38 cells. (,4) Indirect immuno- 
fluorescent staining with anti-42-kD peptide antibody; (B) staining 
with a murine anti-receptor antibody. See Materials and Methods 
and Fig. 4 legend for experimental details. The results of fluores- 
cence and phase microscopy are shown in upper and lower panels, 
respectively. 
The results in Figs. 6 and 7 show that receptors, which ac- 
cumulate in the perinuclear region in response to a  brief 
treatment with EGF, rapidly return to the plasma membrane 
upon withdrawal of EGE This contrasts with earlier findings 
on proteolytic degradation of internalized EGF receptors (4, 
14,  16, 38), but supports earlier indirect evidence for EGF 
receptor recycling in hepatocytes (19). The data in Fig.  7 
show that 70-75 % of the receptors which had internalized (in 
response to 40 nM EGF) recycle to the surface after EGF 
withdrawal and that t,~ for the recycling is <15 min. Assum- 
ing that all undegraded immunoreactive receptors can recy- 
cle,  this would indicate that 25-30%  of the receptors  are 
degraded after a 30-min treatment with 40 nM EGE This is 
consistent  with  the  reported  t,~  of  1-1.5  h  for  receptor 
degradation at saturating concentrations of EGE  We have 
measured receptor recycling under conditions of EGF with- 
drawal,  and  the  results  suggest  that  all  undegraded  im- 
munoreactive receptors rapidly recycle to the cell surface. 
The rapidity of this phenomenon suggests that in the pres- 
ence of EGF a dynamic equilibrium between endocytic in- 
take and recycling to surface determines the amount of recep- 
tors in the perinuclear region.  An additional parameter is 
Murthy et al. Recycling of EGF Receptor Kinase  339 Figure 6. Return ofperinuclear receptors to the plasma membrane upon EGF withdrawal. (A) Indirect immunofluorescent staining of per- 
meabilized and nonperrneabilized mouse 3T3 cells with anti-170-kD receptor antibody. (B) Indirect immunofluorescent staining of  permea- 
bilized 3T3 cells with anti-42-kD peptide antibody. Murine 3T3 cells were treated with 20 nM EGF at 37°C as described in Fig. 4 legend, 
then rapidly washed with DME-BSA and incubated at 37°C for the indicated times in EGF-free DME-BSA. In certain experiments,  10 mM 
methylamine or 20 pg/rnl cycloheximide was included in the medium as indicated. Then the monolayers were fixed, left nonpermeabilized 
(as in A, left),  or were permeabilized with Triton X-100 (A, right; B) and subjected to indirect immunofluorescent staining with antibody 
as described in Materials and Methods. The results of fluorescence and phase microscopy are shown in upper and lower panels, respectively. 
The two different scale bars in A represent different magnifications for nonpermeable  and permeabilized  cells. 
provided by the irreversible step of receptor degradation (and 
of course receptor biosynthesis). These phenomena are EGF 
concentration-dependent, i.e., at sub-saturating (mitogenic) 
concentrations  of EGF  the  dynamic  equilibrium  between 
surface-localized and internal receptors is likely to be more 
evident, and the t~ for receptor degradation is likely to be 
higher. Overall it appears that at a given time a major frac- 
tion (,,~70%) of the internalized EGF receptors recycle to the 
plasma membrane while a minor population (<30%) under- 
goes degradation. The cumulative effect of this degradation, 
although not sizable after a brief incubation (as in Figs. 6 and 
7),  becomes appreciable after a  2  h  (or greater) period of 
treatment of cells with saturating concentrations of EGF (14, 
16,  38).  The  resultant  down-regulation  (1,  8)  reduces  the 
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Figure 7. Recycling of internalized EGF receptors. Washed mono- 
layers of 3T3 cells in 35-mm dishes were incubated at 37°C for 30 
min in DME with 1 mg/ml BSA containing either no addition (e, 
x), or 10 mM methylamine (O). Then some dishes (-20 min point) 
were tested for t25I-EGF binding activity as described  in the last 
paragraph  of Materials  and  Methods.  Others  were  incubated  at 
37°C for 20 min in DME-BSA containing 40 nM EGF (unlabeled) 
without  (e, x) or with (O)  10 mM methylamine.  After washing 
with DME-BSA,  some dishes  (0 time) were tested for ~5I-EGF 
binding activity. Others were kept at 37°C (e, O) or 4°C (x) for 
the indicated times in 1 ml of DME-BSA without ($, x) or with 
(O) 10 mM methylamine and then tested for t25I-EGF binding ac- 
tivity.  For each time point  control  ~25I-EGF binding  was deter- 
mined in cells that were treated identically as above except for the 
absence of EGF. 100% binding represents 180,000-2130,000 cpm of 
specifically bound ~2SI-EGF  radioactivity. Nonspecific binding was 
•10,000  cpm. 
number of functional receptors that can return to the cell sur- 
face (see last paragraph or Results). 
Direct evidence for recycling exists for the receptors for 
asialoglycoproteins, transferrin, and low density lipoprotein 
(3, 9, 22). It should be noted that these ligand accumulatory 
receptors are markedly different from the EGF receptor and 
other growth factor receptor kinases in the smallness and ap- 
parent nonfunctionality of their cytoplasmic domains (18, 28, 
43).  Thus the structural  parameters that control migration 
and  trafficking  of ligand-accumulatory  receptors  may  be 
quite different from those of receptor tyrosine kinases. In this 
context it  is  worth  noting  that indirect  evidence for recy- 
cling has been reported for at least another receptor kinase, 
the insulin receptor (27),  and that a  dual subcellular loca- 
tion has been demonstrated for a related tyrosine kinase, the 
pp6(F  -~rc (33). 
It is of interest to note that drugs such as methylamine (29) 
and monensin (3) inhibit the return of perinuclear receptors 
to the cell  surface (Fig.  6).  The state of activation of the 
receptor kinases trapped inside by these drugs will depend 
upon a variety of factors such as EGF occupancy and/or tyro- 
sine phosphorylation.  In any event, the normal process of 
receptor regeneration,  involving return  to the cell  surface 
and re-occupancy by EGF, will be blocked by these drugs. 
If the continuing cycling of EGF receptors (from the inside 
to outside and back to inside) is needed for a critical intracel- 
lular  phosphorylation  event or  the  amassing of a  critical 
mitogenic signal, then any long-term interference with this 
process by drugs is likely to result in inhibition of receptor 
mitogenicity.  On  the  other  hand,  a  short-term  incubation 
with these drugs may transiently increase the amount of ac- 
tive receptors in the perinuclear region and thereby have a 
slight activating effect. 
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